NRX Pharmaceuticals, Inc. Proceeds from Issuance of Private Placement
NRX Pharmaceuticals, Inc. (NRXP) reported Proceeds from Issuance of Private Placement of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-03-23
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2025-12-31 was $0.00.
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2025-09-30 was $0.00.
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2025-06-30 was $0.00.
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2024 was $1.03M, a 87.36% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2023 was $8.12M.
- NRX Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2021 was $11.05M.
| Period end | Proceeds from Issuance of Private Placement | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 6 month as first filed | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 9 month as first filed | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $0.00 10-Q · filed 2025-08-18 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $1.03M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $1.03M 10-Q · filed 2025-11-14 | $1.03M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $1.03M 10-Q · filed 2025-08-18 | $1.03M derived: sum of 3 quarters · filed 2025-08-18 | $1.03M derived: sum of 4 quarters · filed 2025-08-18 | |||
| 2024-03-31 | $1.03M 10-Q · filed 2025-05-15 | $1.03M derived: sum of 2 quarters · filed 2025-05-15 | $1.03M derived: sum of 3 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-14 | $8.12M 10-K · filed 2025-03-14 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $8.12M 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $8.12M 10-Q · filed 2024-08-14 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $11.05M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.05M 10-Q · filed 2022-11-14 | $11.05M 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $11.05M 10-Q · filed 2022-08-15 | $11.05M 10-Q · filed 2021-08-16 | |||||
| 2017-11-29 | $9.22M 10-Q · filed 2021-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |